Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation

PurposeTo externally validate the model predictions of a DATATOP cohort analysis through application of clinical trial simulation with the study design of the ELLDOPA trial.MethodsThe stochastic pharmacokinetic-pharmacodynamic and disease progress model was developed from the large DATATOP cohort of patients followed for 8 years. ELLDOPA was designed to detect a difference between placebo and levodopa treated arms in the total Unified Parkinson’s Disease Rating Scale (UPDRS) taken at baseline and following 2 weeks levodopa washout after 40 weeks of treatment. The total UPDRS response was simulated with different assumptions on levodopa effect (symptomatic with/without disease modifying capability) and washout speed of symptomatic effect.ResultsThe observed results of ELLDOPA were similar to the model predictions assuming levodopa slows disease progression and has a slow washout of symptomatic effect.ConclusionsThis simulation work confirmed the conclusion of the DATATOP analysis finding that levodopa slows disease progression. The simulation results also showed that a dose-related increased rate of progression in Parkinson’s disease, obscured by symptomatic benefit, is very unlikely. Finally, the simulation results also shown that 2 weeks washout period was not adequate to completely eliminate the symptomatic benefits of levodopa.

[1]  Y. Agid,et al.  Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions , 1998, Annals of neurology.

[2]  K. Sewing,et al.  Effects of histamine on protein and glycoprotein production of isolated pig gastric mucosal cells. , 1990, Pharmacology.

[3]  J. Nutt,et al.  Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[4]  R. Hauser,et al.  Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[5]  J. Hubble,et al.  Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[6]  K. Sethi,et al.  Levodopa and the progression of Parkinson’s disease , 2005, Current neurology and neuroscience reports.

[7]  M. Musicco,et al.  Mortality associated with early and late levodopa therapy initiation in Parkinson's disease , 1990, Neurology.

[8]  H. Baas,et al.  Concentration‐response relationship of levodopa in patients at different stages of Parkinson's disease , 1998, Clinical pharmacology and therapeutics.

[9]  C. Mytilineou,et al.  Toxic and Protective Effects of l‐DOPA on Mesencephalic Cell Cultures , 1993, Journal of neurochemistry.

[10]  Nicholas H. G. Holford,et al.  Importance of Within Subject Variation in Levodopa Pharmacokinetics: A 4Year Cohort Study in Parkinson’s Disease , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  N H Holford,et al.  Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.

[12]  J. Nutt,et al.  Evolution of the response to levodopa during the first 4 years of therapy , 2002, Annals of neurology.

[13]  Y. Michotte,et al.  Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. , 1989, Neurology.

[14]  J. Bennett,et al.  L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? , 1994, Neuroreport.

[15]  S. Aquilonius,et al.  Pharmacokinetics and effects of levodopa in advanced Parkinson's disease , 2004, European Journal of Clinical Pharmacology.

[16]  J. Nutt,et al.  Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson’s Disease , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  D. Riley.  Is levodopa toxic to human substantia nigra? , 1998, Movement disorders : official journal of the Movement Disorder Society.

[18]  Nicholas H. G. Holford,et al.  A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.

[19]  D. Mould,et al.  Disease Progress Models , 2007 .

[20]  K C Yeh,et al.  Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. , 1989, Neurology.

[21]  L. Schiffer,et al.  Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.

[22]  M. Muenter,et al.  Multi‐center study of Parkinson mortality with early versus later dopa treatment , 1987, Annals of neurology.

[23]  A. Barzilai,et al.  Levodopa induces apoptosis in cultured neuronal cells—A possible accelerator of nigrostriatal degeneration in Parkinson's disease? , 1997, Movement disorders : official journal of the Movement Disorder Society.

[24]  J. Dobkin,et al.  Cerebral vasocapacitance and TIAs , 1989, Neurology.

[25]  A. Atkinson,et al.  Principles of Clinical Pharmacology , 2001 .

[26]  M. Yahr,et al.  Autopsy findings in parkinsonism following treatment with levodopa , 1972, Neurology.

[27]  L. Sheiner,et al.  Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.

[28]  Yuko Y Palesch,et al.  Non-linearity of Parkinson’s disease progression: implications for sample size calculations in clinical trials , 2005, Clinical trials.

[29]  M. Mena,et al.  Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid , 1993, Neuroreport.

[30]  S Fahn,et al.  Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. , 1999, Archives of neurology.

[31]  J. Cedarbaum,et al.  A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). , 1989, Neurology.